CA2304498C - Aerosol medication delivery apparatus and system - Google Patents
Aerosol medication delivery apparatus and system Download PDFInfo
- Publication number
- CA2304498C CA2304498C CA002304498A CA2304498A CA2304498C CA 2304498 C CA2304498 C CA 2304498C CA 002304498 A CA002304498 A CA 002304498A CA 2304498 A CA2304498 A CA 2304498A CA 2304498 C CA2304498 C CA 2304498C
- Authority
- CA
- Canada
- Prior art keywords
- chamber housing
- medication
- canister
- aerosol
- mouthpiece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/003—Particle size control by passing the aerosol trough sieves or filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
Abstract
An improved aerosol medication delivery apparatus and system. The aerosol medication delivery apparatus includes a canister-holding portion and a chamber housing.
The canister-holding portion has a receptacle for receipt of a pMDI canister containing a medication and a propellant to provide the aerosol medication delivery system. The canister-holding portion has a discharge orifice communicating with the receptacle to direct an aerosol into an interior of the chamber housing at an input end thereof. The chamber housing also has an output end from which medication can be withdrawn by inhalation by a patient. According to one aspect, the aerosol delivery system includes a containment baffle located at the output end of the chamber housing to partially block the output. According to another aspect, the canister-holding portion and the chamber housing are coupled together by a mechanism that provides for the canister-holding portion to be retracted into the chamber housing for storage. The coupling mechanism also allows the canister-holding portion to be extracted from its storage position in the chamber housing and pivoted into position for use when dispensing medication. In another aspect, an aerosol medication apparatus includes a chamber housing with an input end to receive the discharge of a medication from a pMDI canister and an output end including a containment baffle that partially blocks the output end. The pMDI canister may be received in an elastomeric backpiece that is adapted to accommodate various sizes of actuator boot mouthpieces.
The canister-holding portion has a receptacle for receipt of a pMDI canister containing a medication and a propellant to provide the aerosol medication delivery system. The canister-holding portion has a discharge orifice communicating with the receptacle to direct an aerosol into an interior of the chamber housing at an input end thereof. The chamber housing also has an output end from which medication can be withdrawn by inhalation by a patient. According to one aspect, the aerosol delivery system includes a containment baffle located at the output end of the chamber housing to partially block the output. According to another aspect, the canister-holding portion and the chamber housing are coupled together by a mechanism that provides for the canister-holding portion to be retracted into the chamber housing for storage. The coupling mechanism also allows the canister-holding portion to be extracted from its storage position in the chamber housing and pivoted into position for use when dispensing medication. In another aspect, an aerosol medication apparatus includes a chamber housing with an input end to receive the discharge of a medication from a pMDI canister and an output end including a containment baffle that partially blocks the output end. The pMDI canister may be received in an elastomeric backpiece that is adapted to accommodate various sizes of actuator boot mouthpieces.
Description
r AEROSOL MEDICATION DELIVERY
This invention relates to a portable aerosol medication delivery apparatus and 6 system for administering a desired respirable dosage of a medication in aerosol form 7 to a patient's lungs by oral inhalation.
The use of aerosol medication delivery systems to administer medication in I 1 aerosol form to a patient's lungs by inhalation is well known in the art.
12 Conventional aerosol medication delivery systems include pressurized 13 metered-dose inhalers (pMDIs). Conventional pMDls typically have two 14 components: a canister component in which the medication particles are stored under pressure in a suspension or solution form and a receptacle component used to hold and 16 actuate the canister. The canister component typically includes a valved outlet from 17 which the contents of the canister can be discharged. Aerosol medication is dispensed 18 from the pMDI by applying a force on the canister component to push it into the 19 receptacle component thereby opening the valved outlet and causing the medication particles to be conveyed from the valved outlet through the receptacle component and 21 discharged from an outlet of the receptacle component. Upon discharge from the 22 canister, the medication particles are "atomized" fotming an aerosol. It is intended 23 that the patient coordinate the discharge of aerosolizcd medication with his or her 24 inhalation so that the medication particles are entrained in the patient's inspiratory flow and conveyed to the lungs. Typically, pMDls have used propellants, such as 26 chlorofluorocarbons (CFCs), to pressurize the contents of the canister and to propel 27 the medication particles out of the outlet of the receptacle component 28 Although conventional pMDls have been widely used to provide many 29 patients with the benefits of aerosol medication, conventional pMDIs have certain drawbacks. For example, an objective of aerosol therapy has been the optimization of 31 the mass percentage of the respirable dose of an aerosol medication in order to 32 optimize deposition in a patient's lungs to achieve a full therapeutic effect with the I least possible side-effects. Conventional pMDIs may not have always been able to 2 meet this objective.
3 One drawback associated with conventional pMDls relates to the discharge 4 velocity of the aerosol particles. Medication particles are stored under considerable pressure in the pMDI canister and as a consequence, their velocity may be high upon 6 discharge.
7 Among other things, the effect of high velocity contributes to a significant 8 number of aerosol medication particles impacting and depositing in the patient's 9 oropharynx and upper airway rather than continuing their pathway through the upper airway and into the lungs. Such impaction and deposition may result in a significant ] 1 portion of the medication dose being systemically absorbed or ingested. As 12 documented in the literature [J. L. Rau, "Respiratory Care Pharmacology", 4`h ed.
13 (1994, Mosby) at pp. 256-261; K. Meeran, A. Hattersley, J. Burrin, R.
Shiner, K.
14 Ibbertson K., "Oral and Inhaled Corticosteroids Reduce Bone Formation as Shown by Plasma Osteocalcin Levels", Am. J. Respir. Crit. Care Med 151:333-336], systemic 16 absorption or ingestion of aerosol medication may cause a patient adverse side-effects, 17 particularly when the aerosol medication is a corticosteroid. Some of these adverse 18 side-effects include pharyngeal candidiasis, hoarseness, and adrenal suppression.
19 The high velocity of the aerosol medication particles may also accentuate the difficulty of a significant number of patients, particularly the very young and elderly, 21 to coordinate actuation of the pMDI with inhalation of the aerosol medication 22 particles generated. Failure to coordinate the actuation and inhalation maneuvers and 23 failure to inhale slowly, have been documented by the literature [S.P.
Newman, 24 "Aerosol Deposition Considerations in Inhalation Therapy" Chest / 88 / 2 /
August, 1985 / Supplement] as contributing to a significant reduction in the number of aerosol 26 medication partictes inspired and deposited in a patient's lungs.
27 Impaction and deposition of aerosol medication particles on a patient's 28 oropharynx and upper airway may also contribute to an unpleasant taste in a patient's 29 mouth, particularly with certain medication solution or suspension formulations such as flunisolide.
31 In addition to high particle velocity, a significant number of large non-respirable medication particles may be produced upon discharge as a result of the 2 medication suspension or solution formuiation as well as the atomization process. As 3 mentioned above, conventional pMDIs have used CFCs to propel the medication out 4 of the pMDI actuator outlet. In view of environmental concems with CFCs, there has been a growing interest in using non-CFC propellants, such as hydrofluoroalkanes 6 (HFAs).
7 Accordingly, it is an object of the invention to provide for the delivery of 8 respirable medication particles from a pMDI canister with a device that overcomes the 9 disadvantages of the prior art.
-o It is another object to provide a device which reduces the need for a patient to 1 I coordinate activation of a pMDI canister with inhalation.
12 It is a further object to provide a device that reduces the delivery of non-13 respirable medication particles from a pMDI canister to a patient.
14 It is yet another object to provide a device that reduces the impaction of medication particles on a patient's oropharynx and upper airway.
16 It is still another object to provide a device for the delivery of aerosol 17 medication from a pMDI canister that uses an HFA propellant instead of a CFC
18 propellant.
SUMMARY OF THE INVENTION
21 In order to address the above noted objectives, as well as other objectives, the 22 present invention provides an improved aerosol medication delivery apparatus. The 23 aerosol medication delivery apparatus includes a canister-holding portion and a 24 chamber housing. The canister-holding portion has a receptacle for receipt of a pMDI
canister containing a medication and a propellant. The canister-holding portion has a 26 discharge orifice communicating with the receptacle to direct an aerosol into an 27 interior of the chamber housing at an input end thereof. The chamber housing also 28 has an output end from which medication can be withdrawn by inhalation by a patient.
29 The canister-holding portion and the chamber housing are coupled together by a mechanism that provides for the canister-holding portion to be retracted into the 31 chamber housing for storage. The coupling mechanism also allows the canister-1 holding portion to be extracted from its storage position in the chamber housing and 2 pivoted into position for use when dispensing medication. According to one aspect of 3 the present invention, the aerosol delivery system includes a containment baffle 4 located at the output end of the chamber housing to partially block the output end.
According to another aspect, the canister-holding portion and the chamber 6 housing are coupled together by a mechanism that provides for the canister-holding 7 portion to be retracted into the chamber housing for storage. The coupling mechanism 8 also allows the canister-holding portion to be extracted from its storage position in the 9 chamber housing and pivoted into position for use when dispensing medication.
In another aspect, an aerosol medication delivery apparatus includes a chamber 11 housing with an input end an output end. The input end receives the discharge of a 12 medication from a pMDI canister and the output end includes a containment baffle 13 that partially blocks the output end. The pMDI canister is received in an elastomeric 14 backpiece that is adapted to accommodate various sizes of actuator boot mouthpieces.
17 FIG. I is a perspective view of an aerosol medication delivery system in 18 accordance with an embodiment of the present invention.
19 FIG. 2 is an exploded view of the aerosol medication delivery system of FIG.
1.
21 FIG. 3 is a side view of the aerosol medication delivery system of FIG. 1.
22 FIG. 4 is a side sectional view of the aerosol medication delivery system of 23 FIG. 1.
24 FIG. 5 is a front view of the canister-holding portion shown in FIG. 1.
FIG. 6 is a sectional view of the canister-holding portion of FIG. 5 taken along 26 line 6--6'.
27 FIG. 7 is a side view of the downstream housing portion in FIG 1.
28 FIG. 8 is an end view of the downstream housing portion shown in FIG. 7.
29 FIG. 9 is a sectional view of the downstream housing portion shown in FIG.
taken along line 9-9'.
31 FIG. 10 is a sectional view of the embodiment in FIG. 1 in a retracted position.
1 FIG. 11 is an enlarged sectional view of an inside upstream portion of the 2 chamber housing of FIG. 1 showing part of the coupling mechanism.
3 FIG. 12 is a perspective view of an aerosol medication delivery system in 4 accordance with another embodiment of the present invention.
FIG. 13 is an end view of the embodiment of FIG. 12.
6 FIGS. 14-16 each show an end view of an alternative embodiment of the 7 containment baffle shown in FIG. 8.
8 FIG. 17 is a side sectional view of another altemative embodiment of the 9 aerosol medication delivery apparatus of FIG. 1.
FIG. 18 is a end view of the embodiment shown in FIG. 17 11 FIG. 19 is a side sectional view of yet another alterttative embodiment of the -2 aerosol medication delivery apparatus of FIG. 1.
13 FIG. 20 is an end view of the containment baffle of the embodiment of FIG.
14 19.
FIG. 21 is a side sectional view of yet another alternative embodiment of the 16 aerosol medication delivery apparatus of FIG. 1.
17 FIG. 22 is an end view of the containment baffle of the embodiment of FIG.
18 21.
DETAILED DESCRIPTION OF THE
22 I. General 23 FIGS. 1-11 show an embodiment of an aerosol medication delivery apparatus 24 10. The apparatus 10 comprises a pMDI canister-holding portion (or dispenser) 22 coupled to a chamber housing portion 24. 'Fhe delivery apparatus 10 together with a 26 pMDI canister 30 form an aerosol therapy system 12.
27 The canister-holding portion 22 has a generally rectangular cross-sectional 28 shape that defines a receiving area or receptacle 28 for receipt therein of the pMDI
29 canister 30. The receiving area 28 is suited for conventional pMDI
canisters of well-known construction. The pMDI canister 30 contains a medication suspension or 31 solution under pressure. In the present embodiment, an HFA propelled medication i suspension or solution formulation is used. In one embodiment, the liquid medicatiori 2 is flunisolide. Other propellants and other medications may also be used.
3 Referring to FIG. 6, the pMDI canister 30 has a stem 32 that permits a portion 4 of the medication suspension or solution to be discharged therefrom upon application of a force on the stem 32. When the pMDI canister 30 is located in the receiving area 6 28 of the canister-holding portion 22, the canister stem 32 is positioned in a vertical 7 channel or well 34 formed in the bottom of the canister-holding portion 22.
When the 8 stem 32 of the canister 30 is located in the vertical channel 34, ambient air can pass 9 into the chamber via a passageway 33. A horizontal passage 35 communicates with the vertical channel 34. The horizontal passage 35 leads to a discharge orifice 36 11 located opposite from the vertical channel 34.
13 H. Chamber Housing 14 Referring to FIG. 6, the discharge orifice 36 forms the passage by which medication particles from the pMDI canister 30 can exit the canister holding portion 16 22 and enter into the chamber housing portion 24. The chamber housing 24 has an 17 input end 46 and an output end 48 that define the ends of an interior space 39.
18 Referring to FIGS. 2- 4, in a present embodiment, the chamber housing 19 portion 24 is formed of two parts: a main housing portion 43 and a downstream portion 45. The main housing portion 43 and the downstream portion 45 together 21 define the interior space 39 of the chamber housing portion 24. The downstream 22 portion 45 has retaining fingers 47 that engage in slots 49 on each side of the main 23 housing portion 43. In the embodiment shown, the main housing portion 43 and the 24 downstream portioi145 easily snap together and can be easily disconnected for cleaning.
26 Referring to FIG. 2, the main housing portion 43 has a curved cross section.
27 In a present embodiment, the curved cross-section has a complex geometry formed of 28 a plurality of radii to form a convenient, easy-to-use shape.
ITI. Containment Baflle/Mouthpiece 31 Referring to FIGS. 2 and 7-9, a containment baffle 51 is located in the 1 downstream portion 45 at the outlet of the chamber housing 24. The containment 2 baffle 51 is located centrally and forms a distal wall 53 of the downstream portion 45.
3 The containment baffle 51 is positioned so as to partially block the output end 48.
4 The containment baffle 51 reduces the velocity or flow rate or both of the aerosol medication particles on axis 42 of the chamber housing 24. A mouthpiece 55 is 6 located on the outside of the downstream portion 45 and includes the containment 7 baffle 51 at an outlet end thereof.
8 As shown in FIGS. 7-9, the containment baffle 51 has a concave-shaped center 9 portion 62. In the embodiment shown, the perimeter of the concave-shaped center portion 62 of the containment baffle 51 has generally straight vertical sides 57A and t 1 57B, a curved top side 57C. and a curved bottom side 57D. The perimeter of the 12 concave-shaped center portion 62 of the containment baffle 51 conforms generally in 13 shape to the cross-sectional shape of the mouthpiece 55. The concave-shaped center 14 portion 62 of the containment baffle 51 is aligned with a central axis 42 of the chamber housing 24 and is directly in line with the discharge orifice 36.
Aerosol 16 medication particles that have a flow path away from the axis of symmetry 42 tend to 17 have a velocity that is lower than that of particles near to the axis of symmetry. The 18 center portion 62 of the containment baffle 51 reduces the forward, on-axis velocity 19 and simultaneously acts as an impaction surface for on-axis projectile aerosol medication particles. At the same time the center portion 62 allows slower moving 21 aerosol medication particlcs to migrate towards the sides 52 of the chamber housing 22 24. The forward velocity of the aerosol medication particles away from the axis 42 23 along the chamber length is also reduced by the outer portion 66 of the containment 24 baffle 51 that is concentric with the concave shaped center portion 62.
Positioned between the center and outer portions 62 and 66 is an inhalation 26 opening area 70. In the embodiment, the inhalation opening area 70 is defined by four 27 openings 70A-70D. The openings are arcuate in shape and conform to the periphery 28 of the central portion 62. Each of the openings 70 has a length of approximately. 9 29 mm and a width of approximately 2 mm. The size, shape and number of openings may vary depending on the medication suspension or solution formulation and/or 31 propellant used.
I In a present embodiment, the aerosol delivery apparatus 10 includes a cap 74 2 which can be placed over the mouthpiece 55 to prevent contaminants from entering 3 the interior space 39. The cap 74 serves to protect the mouthpiece 55 and keep it 4 relatively clean.
6 IV. Operation 7 To use the aerosol delivery apparatus 10 for delivery of an aerosol medication, 8 the canister-holding portion 22 and chamber housing 24 are arranged as shown in 9 FIG. 1. The cap 74 is removed and the pMDI canister 30 is located in the receiving area 28 with the stem 32 inserted into the channel 34 formed in the bottom of the I i receiving area 28 as shown in FIG. 6. As mentioned above, the apparatus 10 receives 12 the pMDI canister 30 which is operated conventionally (i.e. by pressing down on the 13 pMDI canister 30 which is located stem-side-down in the receiving area 28).
Upon 14 depression of the stem 32, the medication suspension or solution formulation in the pMDI canister 30 is discharged out of an opening 33 at the tip of the stem 32.
As the 16 medication suspension or solution formulation flows through the horizontal channel 17 35 and out of the discharge orifice 36, the propellant and suspending liquid or solvent t 8 evaporate and the medication particles are discharged in aerosol form into the 19 surrounding envirotunent inside the chamber volume 39. Upon discharge from the pMDI canister 30, the medication particles in the aerosol plume may have an average 21 speed, size distribution and/or flow rate that may not be ideal for direct inhalation by a 22 patient. However, once the aerosol medication is inside the chamber volume 39, the 23 proportion of larger non-respirable particies available on inhalation is minimized and 24 the dose of respirable particles is optimized. The aerosol medication particles are withdrawn therefrom by having the patient, whose mouth is around the mouthpiece 26 55, inhale through the inhalation opening area 70. The aerosol medication particles 27 will then flow through the inhalation opening area 70 and into the patient's mouth.
29 V. Retraction for Storage A further feature of the aerosol medication apparatus 10 is that it can be 31 retracted for convenient storage and portability. For this purpose, the chamber I housing 24 is coupled to the canister-holding portion 22 via a coupling mechanism 94 2 as shown in FIG. 11. The coupling mechanism 94 permits the aerosol medication 3 delivery apparatus 10 to be compactly stored by pivoting the canister-holding portion 4 22 from the position of FIGS. 1-4 to a horizontal position and then pushing the canister-holding portion 22 so that it translationally moves into the chamber housing 6 24 as shown in FIG. 10.
7 Referring to FIG. 11, the pivoting and translational movement is accomplished 8 by the structure of the coupling mechanism 94. In particular, the coupling mechanism 9 94 includes a pair of slots 96 formed in the chamber housing 24, wherein each slot 96 has an open end 98 and a closed end 100. As shown in FIG. 5, the canister-holding 11 portion 22 has a pair of pegs 102, attached thereto. In addition, the interior portion of 12 the chamber housing 24 has multiple parallel tracks 104 (shown in FIG. 10) which 13 guide the canister-holding portion 22 into the chamber housing 24.
14 To connect the chamber housing 24 and the canister-holding portion 22 together, a top end 109 of the canister-holding portion 22 is first inserted into the 16 output end 48 of the chamber housing 24 and translationally moved towards and past 17 the input end 46 so that the pegs 102 are inserted into the open ends 98 of the 18 corresponding slots 96. Each of the pegs 102 can then translationally move within its 19 respective slot 96 to the closed end 100 thereof. Thus, the canister-holding portion 22 is telescopically received within the chamber housing 24 during translational 21 movement and is able to move from the retracted position of FIG. 10 to an extended 22 position. At the extended position, both pegs 102 contact the closed ends 100 of their 23 corresponding slots 96 and the canister-holding portion 22 is then allowed to pivot to 24 the position of FIG. 4 so that the patient can use the apparatus 10. The end of the canister-holding portion 22 is curved so as to allow it to pivot relative to the chamber 26 housing 24. The foregoing coupling and retraction mechanism allow for easy use, 27 transport, and lower manufacturing costs.
28 To facilitate handling by the patient, a plurality of ribs 77 may be located 29 along the front and rear sides of the canister-holding portion 22 close to the top edge 109 thereof. These ribs 77 remain exposed when the canister-holding portion 22 is 31 retracted into the chamber portion 24 so that the patient can use these ribs to help grip I the end of the canister-holding portion 22 in order to withdraw it from the chamber 2 portion 24. After use by the patient, the cap 74 can be placed back over the 3 mouthpiece 55.
VI. Advantages of Disclosed Embodiment 6 With the embodiment disclosed above, the end result of combining the 7 specified inhalation opening area 70, the chamber housing 24, and the containment 8 baffle 51 is to administer a controllable and desired respirable dose of aerosol 9 medication to a patient for inhalation into the lungs. Further, the disclosed embodiment provides advantages over prior devices in that it incorporates an i- integrated actuator and is easier to use and is easier to store and carry given its smaller 12 size.
13 An advantageous feature of the disclosed embodiment is provided by the 14 containment baffle 51. As mentioned above, the velocity of the aerosol medication particles nearest the axis of synunetry 42 will typically be greater than that of aerosol 16 medication particles that are located further from the axis 42. The velocity of the 17 aerosol medication particles near the axis 42 may be so large as to reduce the 18 effectiveness of delivering the medication to the patient because it will cause a 19 significant portion of the aerosol medication particles to impact on the oropharyngeal region and upper airway where they have no therapeutic value and, in the case of 21 medication such as cort icosteroids. may give rise to adverse side-effects.
The 22 containment baffle 51 overcomes this potential problem by isolating the patient's 23 mouth from the location at which the greatest risk of high velocity impaction may 24 occur. The containment baffle provides this solution in a manner that is relatively inexpensive and easy to manufacture.
26 The disclosed aerosol medicatioii delivery apparatus optimizes the deposition 27 of respirable aerosol medication particles in a patient's lungs to provide a desired 28 therapeutic effect. The aerosol medication delivery apparatus also reduces the 29 importance of coordination between the actuation and inhalation maneuvers and reduces or eliminates possible side-effects caused by aerosol medication formulations 31 consisting of corticosteroids. The aerosol medication delivery apparatus also reduces I or eliminates the unpleasant taste associated with aerosol medication formulations 2 such as flunisolide and allows for convenient portability and quick use.
3 In the case of pMDls that use HFA as a propellant for flunisolide, the present 4 embodiment provides a particular advantage. Through use of the present embodiment, the respirable dosage of flunisolide delivered to the patient can be 6 controlled in a manner to closely conform to the dosage of flunisolide that had been 7 delivered using conventional prior art systems that used prior propellants, such as 8 CFC. In this manner, the dosage of flunisolide can be consistently maintained, 9 thereby benefiting administration of such medication to patients.
The shape, size, and number of openings in the inhalation opening area may 11 vary in order to ensure the administration of a desired respirable dose of a specific 12 pMDI formulation. Upon discharge the on-axis aerosol medication particles, which 13 are generally non-respirable and have a higher inertia than the respirable particles, 14 collide with the interior center portion of the containment baffle resulting in a reduction in the number of larger (non-respirable) aerosol medication particles, and 16 the division of larger (non-respirable) aerosol medication particles into smaller 17 respirable particles.
18 By sealing off (except for the inhalation opening area) the output end of the 19 chamber, the containment baffle contributes to maintaining a high pressure zone in the chamber which allows for the deflection of most slower moving respirable aerosol 21 medication particles away from the containment baffle and into the chamber for 22 containment until inhaled by the patient through the inhalation opening area. The 23 containment of the respirable aerosol medication particles in the chamber provides the 24 patient with more time to inhale the aerosol medication particles and, therefore, reduces the importance of exact coordination between the discharge maneuver and 26 inhalation.
28 VII. Exemplary embodiment 29 In one exemplary embodiment, shown in FIGS. 1-1 l, the canister-holding portion 22 is approximately 7.5 cm in height and is approximately 2.5 by 2.5 cm in 31 cross section. The chamber housing 24 is approximately 8 cm in length and has an I oval-shaped cross section with dimensions of approximately 49 mm by 33 mm.
The 2 mouthpiece 55 is approximately 1.5 cm in length. The canister-holding portion, the 3 chamber housing, and the end cap are formed of a suitable hard, durable plastic, such 4 as polypropylene. The discharge orifice 36 has a diameter of approximately 0.011 inches. In a present embodiment, the containment baffle 51 has a width of 6 approximately 27 mm and a height of approximately 15 mm at the center and 5 mm 7 at the side edges.
8 For purposes of this embodiment, it is assumed that the pMDI canister 9 contains a 0.06% w/v to 0.24% w/v mixture of liquid medication, such as flunisolide in ethanolic solution and HFA as a propellant. It is understood that the pMDI
canister 11 30 can also contain other liquids and other mixtures without departing from the spirit 12 of the invention.
14 VIII. Alternative embodiments Referring to FIGS. 12 and 13, another embodiment of an aerosol delivery 16 apparatus 110 is shown. This embodiment is similar to the embodiment shown in 17 FIGS. 1-11 and like components are labeled with the same numerals. In the 18 embodiment of FIGS. 12 and 13, the containment baffle 151 is located at an upstream 19 end of the passageway defined in the mouthpiece 55. The containment baffle 151 in this embodiment is convex in shape and diverts flow around an on-axis trajectory. In 21 the embodiment of FIGS. 12 and 13, a chamber housing 124 has four squared-off 22 sides 125, 126, 127, and 128. 'fhe squared-off sides may facilitate grippine of the 23 device.
24 Referring to FIGS. 14-16, there are depicted alternative embodiments of the containment baffle. In FIG. 14, a containment baffle 251 has a screen-like structure 26 forming a plurality of openings defined between a crisscrossed mesh 252.
The surface 27 area provided by the mesh 252. combined with the relatively small areas of the 28 openings, serves to prevent aerosol particles having a high velocity from passing to 29 the patient. In FIG. 15, a containment baffle 351 has a plurality of small circular openings formed around a periphery of a solid central portion 362. Like the previous 31 embodiments, the embodiment of FIG. 15 provides a surface area 362, combined with 1 the relatively small openings, serves to prevent aerosol particles having a high 2 velocity from passing to the patient. In FIG. 16, a containment baffle 451 has four 3 relatively large openings formed around the periphery a solid dish-shaped central 4 portion 462. The dish-shaped central portion 462 is connected to the remainder of the chamber body by one or more ribs 463. Like the previous embodiments, the 6 embodiment of FIG. 16 provides a surface area 462, that serves to prevent aerosol 7 particles having a high velocity from passing to the patient.
8 Referring to FIGS. 17 and 18, there is shown an alternate embodiment 512 of 9 an aerosol delivery apparatus. The embodiment of FIGS. 17 and 18 includes an aerosol delivery apparatus 510. The apparatus 510 includes a chamber housing 11 which defines an interior space 539. The apparatus 510 does not include an integrated 12 canister-holding portion. Instead, the chamber housing 524 has a backpiece 527. The 13 backpiece 527 is made of an elastomeric material and is fitted over the upstream end -4 of the chamber housing 524. The backpiece 527 has an opening 529 located centrally therein. The opening 529 is sized to receive the mouthpiece end of a separate pMDI
16 actuator boot. In a preferred embodiment, the opening 529 is sized so that the 17 mouthpiece of the pMDI actuator boot fits snugly into the opening 529.
Because the I8 backpiece 527 is formed of an elastomeric material, it is resilient and the opening 529 19 in the backpiece can be stretched, thereby enabling it acconunodate actuator boot mouthpieces of various sizes and shapes. The backpiece 527 may be similar to the 21 backpiece described in U.S. Pat. No. 4,470.412 or in Ser. No. 08/248,716, the entire 22 disclosure of which is incorporated by reference herein.
23 Located at a downstream end of the chamber housing 524 is a mouthpiece 555.
24 Also located at the downstream end of the chamber housing 524 is a containment baffle 551. The containment baffle 551 may be similar to the containment baffle 51 in 26 the above described embodiment. Located around the periphery of the containment 27 baffle center portion 562 is an inhalation opening area 570. The inhalation opening 28 area 570 includes four arcuate shaped openings. In the embodiment of FIGS.
17 and 29 18, the containment baffle 551 is located at the downstream end of the mouthpiece 555, although in altemative enibodiments, the containment baffle may be located at 31 the upstream end of the mouthpiece or anywhere along the length of the mouthpiece.
1 With the embodiment of FIGS. 17 and 18, the patient inserts the actuator boot 2 mouthpiece into the opening 529 and inserts the pMDI canister into the actuator boot.
3 The patient presses down on the pMDI canister to cause a plume of aerosol 4 medication to be discharged from the stem of the pMDI canister out of the mouthpiece of the actuator boot and into the interior space 539. The patient inhales the aerosol 6 from the interior space 539 via the mouthpiece 555 of the apparatus 510.
7 Another embodiment of the aerosol medication delivery apparatus is shown in 8 FIGS. 19 and 20. An aerosol delivery apparatus 610 includes a chamber housing 624 9 defining an interior space 639. The apparatus 610 also includes an elastomeric backpiece 627 which may be similar to the backpiece in the embodiment shown in t t FIGS. 17 and 18. The apparatus 610 includes a containment baffle 651. The 12 containment baffle 651 is located at the downstream end of the chamber housing 624 13 just upstream of the mouthpiece 655. The containment baffle 651 includes an 14 inhalation opening area 670 located around the periphery of the containment baffle 651. In the embodiment of FIGS. 19 and 20, the containment baffle 651 may be 16 formed of a single piece of material with the chamber housing 624. The mouthpiece 17 655 may be formed of a separate piece of material that is coupled to the downstream 18 end of the chamber housing 624. The embodiment of FIGS. 19 and 20 may be used in 19 a similar manner as the embodiment of FIGS. 17 and 18.
Still another embodiment of the aerosol medication delivery apparatus is 21 shown in FIGS. 21 and 22. This embodiment of the aerosol delivery apparatus is 22 particularly suited for use by a mechanically ventilated patient (i.e. a patient using a 23 ventilator). In FIG. 21, an aerosol delivery apparatus 710 includes components that 24 are similar to the previous embodiments, in particular the embodiment of FIGS. 17 and 18. A chamber housing 724 defines an interior space 739. The apparatus 710 is 26 intended to be positioned in a ventilator circuit, in particular in the air passageway that 27 provides inspiratory air flow from a ventilator to the patient. The chamber housing 28 724 includes a first opening 727 located in a first tubular extension 728 extending 29 from the upstream end 746 of the chamber housing 724 and a second opening located in a second tubular extension 756 that extends from the downstream end 31 of the chamber housing 724. The first opening 727 connects to tubing 731 that leads i to the ventilator (not shown) and the second opening 7551eads to tubing, a mask, a 2 mouthpiece, or other suitable means (not shown) of providing air from the ventilator 3 to the patient. Located at the upstream end of the chamber 724 is a receptacle 722. At 4 the bottom of the receptacle 722 is a well 734 adapted to receive the stem of a pMDI
canister. The wel1734 extends into a rib 735 that extends across the entrance into the 6 interior space 739 of the chamber housing 724. The rib 735 may be located at or 7 along the extension 728. The rib 735 includes a discharge opening 736 that 8 communicates with the we11734. The discharge opening 736 is oriented toward the 9 interior space 739. The receptacle 722, the rib 735, and the discharge opening 736 are integrated with the chamber housing 724 forming part of the aerosol delivery 1 t apparatus 710, (i.e. the receptacle and chamber housing form an integrated unit). In 12 one embodiment the receptacle 722, the rib 735, and the discharge opening 736 are 13 formed of the same piece of material as the chamber housing 724, or alternatively, 14 they may be fonned of separate pieces. Further disclosure regarding an integrated chamber housing and canister receptacle is included in U.S. Pat. No.
5,012,804.
16 Located at the downstream end 748 of the chamber 724 is a containment baffle 17 751. The containment baffle 751 may be located at the downstream end of the 18 chamber housing 724 or along the extension 756. The containment baffle 751 19 includes an inhalation opening area 7701ocated around the periphery of the containment baffle 751.
21 The embodiment of FIGS. 21 and 22 may be used in a similar manner as the 22 device disclosed in U.S. Pat. No. 5,012,804. The apparatus 710 may be positioned in 23 the inspiratory flow path from the ventilator to the patient when the patient is initially 24 placed on the ventilator. The apparatus 710 is then left in place until needed.
Alternatively, the apparatus 710 may be positioned in the inspiratory flow path of the 26 ventilator circuit just prior to when a dose of aerosol medication is to be delivered to a 27 ventilated patient. A pMDI canister is positioned in the receptacle 722 and actuated.
28 The medication from the pMDI canister is conveved with the inspiratory flow from 29 the ventilator to the patient. As in tlie previously described embodiments, the containmcnt baffle 751 reduces on-axis non-respirable particles.
I The invention may be embodied in other forms than those specifically 2 disclosed herein without departing from its spirit or essential characteristics. The 3 described embodiments are to be considered in all respects only as illustrative and not 4 restrictive, and the scope of the invention is commensurate with the appended claims rather than the foregoing descriptions.
The use of aerosol medication delivery systems to administer medication in I 1 aerosol form to a patient's lungs by inhalation is well known in the art.
12 Conventional aerosol medication delivery systems include pressurized 13 metered-dose inhalers (pMDIs). Conventional pMDls typically have two 14 components: a canister component in which the medication particles are stored under pressure in a suspension or solution form and a receptacle component used to hold and 16 actuate the canister. The canister component typically includes a valved outlet from 17 which the contents of the canister can be discharged. Aerosol medication is dispensed 18 from the pMDI by applying a force on the canister component to push it into the 19 receptacle component thereby opening the valved outlet and causing the medication particles to be conveyed from the valved outlet through the receptacle component and 21 discharged from an outlet of the receptacle component. Upon discharge from the 22 canister, the medication particles are "atomized" fotming an aerosol. It is intended 23 that the patient coordinate the discharge of aerosolizcd medication with his or her 24 inhalation so that the medication particles are entrained in the patient's inspiratory flow and conveyed to the lungs. Typically, pMDls have used propellants, such as 26 chlorofluorocarbons (CFCs), to pressurize the contents of the canister and to propel 27 the medication particles out of the outlet of the receptacle component 28 Although conventional pMDls have been widely used to provide many 29 patients with the benefits of aerosol medication, conventional pMDIs have certain drawbacks. For example, an objective of aerosol therapy has been the optimization of 31 the mass percentage of the respirable dose of an aerosol medication in order to 32 optimize deposition in a patient's lungs to achieve a full therapeutic effect with the I least possible side-effects. Conventional pMDIs may not have always been able to 2 meet this objective.
3 One drawback associated with conventional pMDls relates to the discharge 4 velocity of the aerosol particles. Medication particles are stored under considerable pressure in the pMDI canister and as a consequence, their velocity may be high upon 6 discharge.
7 Among other things, the effect of high velocity contributes to a significant 8 number of aerosol medication particles impacting and depositing in the patient's 9 oropharynx and upper airway rather than continuing their pathway through the upper airway and into the lungs. Such impaction and deposition may result in a significant ] 1 portion of the medication dose being systemically absorbed or ingested. As 12 documented in the literature [J. L. Rau, "Respiratory Care Pharmacology", 4`h ed.
13 (1994, Mosby) at pp. 256-261; K. Meeran, A. Hattersley, J. Burrin, R.
Shiner, K.
14 Ibbertson K., "Oral and Inhaled Corticosteroids Reduce Bone Formation as Shown by Plasma Osteocalcin Levels", Am. J. Respir. Crit. Care Med 151:333-336], systemic 16 absorption or ingestion of aerosol medication may cause a patient adverse side-effects, 17 particularly when the aerosol medication is a corticosteroid. Some of these adverse 18 side-effects include pharyngeal candidiasis, hoarseness, and adrenal suppression.
19 The high velocity of the aerosol medication particles may also accentuate the difficulty of a significant number of patients, particularly the very young and elderly, 21 to coordinate actuation of the pMDI with inhalation of the aerosol medication 22 particles generated. Failure to coordinate the actuation and inhalation maneuvers and 23 failure to inhale slowly, have been documented by the literature [S.P.
Newman, 24 "Aerosol Deposition Considerations in Inhalation Therapy" Chest / 88 / 2 /
August, 1985 / Supplement] as contributing to a significant reduction in the number of aerosol 26 medication partictes inspired and deposited in a patient's lungs.
27 Impaction and deposition of aerosol medication particles on a patient's 28 oropharynx and upper airway may also contribute to an unpleasant taste in a patient's 29 mouth, particularly with certain medication solution or suspension formulations such as flunisolide.
31 In addition to high particle velocity, a significant number of large non-respirable medication particles may be produced upon discharge as a result of the 2 medication suspension or solution formuiation as well as the atomization process. As 3 mentioned above, conventional pMDIs have used CFCs to propel the medication out 4 of the pMDI actuator outlet. In view of environmental concems with CFCs, there has been a growing interest in using non-CFC propellants, such as hydrofluoroalkanes 6 (HFAs).
7 Accordingly, it is an object of the invention to provide for the delivery of 8 respirable medication particles from a pMDI canister with a device that overcomes the 9 disadvantages of the prior art.
-o It is another object to provide a device which reduces the need for a patient to 1 I coordinate activation of a pMDI canister with inhalation.
12 It is a further object to provide a device that reduces the delivery of non-13 respirable medication particles from a pMDI canister to a patient.
14 It is yet another object to provide a device that reduces the impaction of medication particles on a patient's oropharynx and upper airway.
16 It is still another object to provide a device for the delivery of aerosol 17 medication from a pMDI canister that uses an HFA propellant instead of a CFC
18 propellant.
SUMMARY OF THE INVENTION
21 In order to address the above noted objectives, as well as other objectives, the 22 present invention provides an improved aerosol medication delivery apparatus. The 23 aerosol medication delivery apparatus includes a canister-holding portion and a 24 chamber housing. The canister-holding portion has a receptacle for receipt of a pMDI
canister containing a medication and a propellant. The canister-holding portion has a 26 discharge orifice communicating with the receptacle to direct an aerosol into an 27 interior of the chamber housing at an input end thereof. The chamber housing also 28 has an output end from which medication can be withdrawn by inhalation by a patient.
29 The canister-holding portion and the chamber housing are coupled together by a mechanism that provides for the canister-holding portion to be retracted into the 31 chamber housing for storage. The coupling mechanism also allows the canister-1 holding portion to be extracted from its storage position in the chamber housing and 2 pivoted into position for use when dispensing medication. According to one aspect of 3 the present invention, the aerosol delivery system includes a containment baffle 4 located at the output end of the chamber housing to partially block the output end.
According to another aspect, the canister-holding portion and the chamber 6 housing are coupled together by a mechanism that provides for the canister-holding 7 portion to be retracted into the chamber housing for storage. The coupling mechanism 8 also allows the canister-holding portion to be extracted from its storage position in the 9 chamber housing and pivoted into position for use when dispensing medication.
In another aspect, an aerosol medication delivery apparatus includes a chamber 11 housing with an input end an output end. The input end receives the discharge of a 12 medication from a pMDI canister and the output end includes a containment baffle 13 that partially blocks the output end. The pMDI canister is received in an elastomeric 14 backpiece that is adapted to accommodate various sizes of actuator boot mouthpieces.
17 FIG. I is a perspective view of an aerosol medication delivery system in 18 accordance with an embodiment of the present invention.
19 FIG. 2 is an exploded view of the aerosol medication delivery system of FIG.
1.
21 FIG. 3 is a side view of the aerosol medication delivery system of FIG. 1.
22 FIG. 4 is a side sectional view of the aerosol medication delivery system of 23 FIG. 1.
24 FIG. 5 is a front view of the canister-holding portion shown in FIG. 1.
FIG. 6 is a sectional view of the canister-holding portion of FIG. 5 taken along 26 line 6--6'.
27 FIG. 7 is a side view of the downstream housing portion in FIG 1.
28 FIG. 8 is an end view of the downstream housing portion shown in FIG. 7.
29 FIG. 9 is a sectional view of the downstream housing portion shown in FIG.
taken along line 9-9'.
31 FIG. 10 is a sectional view of the embodiment in FIG. 1 in a retracted position.
1 FIG. 11 is an enlarged sectional view of an inside upstream portion of the 2 chamber housing of FIG. 1 showing part of the coupling mechanism.
3 FIG. 12 is a perspective view of an aerosol medication delivery system in 4 accordance with another embodiment of the present invention.
FIG. 13 is an end view of the embodiment of FIG. 12.
6 FIGS. 14-16 each show an end view of an alternative embodiment of the 7 containment baffle shown in FIG. 8.
8 FIG. 17 is a side sectional view of another altemative embodiment of the 9 aerosol medication delivery apparatus of FIG. 1.
FIG. 18 is a end view of the embodiment shown in FIG. 17 11 FIG. 19 is a side sectional view of yet another alterttative embodiment of the -2 aerosol medication delivery apparatus of FIG. 1.
13 FIG. 20 is an end view of the containment baffle of the embodiment of FIG.
14 19.
FIG. 21 is a side sectional view of yet another alternative embodiment of the 16 aerosol medication delivery apparatus of FIG. 1.
17 FIG. 22 is an end view of the containment baffle of the embodiment of FIG.
18 21.
DETAILED DESCRIPTION OF THE
22 I. General 23 FIGS. 1-11 show an embodiment of an aerosol medication delivery apparatus 24 10. The apparatus 10 comprises a pMDI canister-holding portion (or dispenser) 22 coupled to a chamber housing portion 24. 'Fhe delivery apparatus 10 together with a 26 pMDI canister 30 form an aerosol therapy system 12.
27 The canister-holding portion 22 has a generally rectangular cross-sectional 28 shape that defines a receiving area or receptacle 28 for receipt therein of the pMDI
29 canister 30. The receiving area 28 is suited for conventional pMDI
canisters of well-known construction. The pMDI canister 30 contains a medication suspension or 31 solution under pressure. In the present embodiment, an HFA propelled medication i suspension or solution formulation is used. In one embodiment, the liquid medicatiori 2 is flunisolide. Other propellants and other medications may also be used.
3 Referring to FIG. 6, the pMDI canister 30 has a stem 32 that permits a portion 4 of the medication suspension or solution to be discharged therefrom upon application of a force on the stem 32. When the pMDI canister 30 is located in the receiving area 6 28 of the canister-holding portion 22, the canister stem 32 is positioned in a vertical 7 channel or well 34 formed in the bottom of the canister-holding portion 22.
When the 8 stem 32 of the canister 30 is located in the vertical channel 34, ambient air can pass 9 into the chamber via a passageway 33. A horizontal passage 35 communicates with the vertical channel 34. The horizontal passage 35 leads to a discharge orifice 36 11 located opposite from the vertical channel 34.
13 H. Chamber Housing 14 Referring to FIG. 6, the discharge orifice 36 forms the passage by which medication particles from the pMDI canister 30 can exit the canister holding portion 16 22 and enter into the chamber housing portion 24. The chamber housing 24 has an 17 input end 46 and an output end 48 that define the ends of an interior space 39.
18 Referring to FIGS. 2- 4, in a present embodiment, the chamber housing 19 portion 24 is formed of two parts: a main housing portion 43 and a downstream portion 45. The main housing portion 43 and the downstream portion 45 together 21 define the interior space 39 of the chamber housing portion 24. The downstream 22 portion 45 has retaining fingers 47 that engage in slots 49 on each side of the main 23 housing portion 43. In the embodiment shown, the main housing portion 43 and the 24 downstream portioi145 easily snap together and can be easily disconnected for cleaning.
26 Referring to FIG. 2, the main housing portion 43 has a curved cross section.
27 In a present embodiment, the curved cross-section has a complex geometry formed of 28 a plurality of radii to form a convenient, easy-to-use shape.
ITI. Containment Baflle/Mouthpiece 31 Referring to FIGS. 2 and 7-9, a containment baffle 51 is located in the 1 downstream portion 45 at the outlet of the chamber housing 24. The containment 2 baffle 51 is located centrally and forms a distal wall 53 of the downstream portion 45.
3 The containment baffle 51 is positioned so as to partially block the output end 48.
4 The containment baffle 51 reduces the velocity or flow rate or both of the aerosol medication particles on axis 42 of the chamber housing 24. A mouthpiece 55 is 6 located on the outside of the downstream portion 45 and includes the containment 7 baffle 51 at an outlet end thereof.
8 As shown in FIGS. 7-9, the containment baffle 51 has a concave-shaped center 9 portion 62. In the embodiment shown, the perimeter of the concave-shaped center portion 62 of the containment baffle 51 has generally straight vertical sides 57A and t 1 57B, a curved top side 57C. and a curved bottom side 57D. The perimeter of the 12 concave-shaped center portion 62 of the containment baffle 51 conforms generally in 13 shape to the cross-sectional shape of the mouthpiece 55. The concave-shaped center 14 portion 62 of the containment baffle 51 is aligned with a central axis 42 of the chamber housing 24 and is directly in line with the discharge orifice 36.
Aerosol 16 medication particles that have a flow path away from the axis of symmetry 42 tend to 17 have a velocity that is lower than that of particles near to the axis of symmetry. The 18 center portion 62 of the containment baffle 51 reduces the forward, on-axis velocity 19 and simultaneously acts as an impaction surface for on-axis projectile aerosol medication particles. At the same time the center portion 62 allows slower moving 21 aerosol medication particlcs to migrate towards the sides 52 of the chamber housing 22 24. The forward velocity of the aerosol medication particles away from the axis 42 23 along the chamber length is also reduced by the outer portion 66 of the containment 24 baffle 51 that is concentric with the concave shaped center portion 62.
Positioned between the center and outer portions 62 and 66 is an inhalation 26 opening area 70. In the embodiment, the inhalation opening area 70 is defined by four 27 openings 70A-70D. The openings are arcuate in shape and conform to the periphery 28 of the central portion 62. Each of the openings 70 has a length of approximately. 9 29 mm and a width of approximately 2 mm. The size, shape and number of openings may vary depending on the medication suspension or solution formulation and/or 31 propellant used.
I In a present embodiment, the aerosol delivery apparatus 10 includes a cap 74 2 which can be placed over the mouthpiece 55 to prevent contaminants from entering 3 the interior space 39. The cap 74 serves to protect the mouthpiece 55 and keep it 4 relatively clean.
6 IV. Operation 7 To use the aerosol delivery apparatus 10 for delivery of an aerosol medication, 8 the canister-holding portion 22 and chamber housing 24 are arranged as shown in 9 FIG. 1. The cap 74 is removed and the pMDI canister 30 is located in the receiving area 28 with the stem 32 inserted into the channel 34 formed in the bottom of the I i receiving area 28 as shown in FIG. 6. As mentioned above, the apparatus 10 receives 12 the pMDI canister 30 which is operated conventionally (i.e. by pressing down on the 13 pMDI canister 30 which is located stem-side-down in the receiving area 28).
Upon 14 depression of the stem 32, the medication suspension or solution formulation in the pMDI canister 30 is discharged out of an opening 33 at the tip of the stem 32.
As the 16 medication suspension or solution formulation flows through the horizontal channel 17 35 and out of the discharge orifice 36, the propellant and suspending liquid or solvent t 8 evaporate and the medication particles are discharged in aerosol form into the 19 surrounding envirotunent inside the chamber volume 39. Upon discharge from the pMDI canister 30, the medication particles in the aerosol plume may have an average 21 speed, size distribution and/or flow rate that may not be ideal for direct inhalation by a 22 patient. However, once the aerosol medication is inside the chamber volume 39, the 23 proportion of larger non-respirable particies available on inhalation is minimized and 24 the dose of respirable particles is optimized. The aerosol medication particles are withdrawn therefrom by having the patient, whose mouth is around the mouthpiece 26 55, inhale through the inhalation opening area 70. The aerosol medication particles 27 will then flow through the inhalation opening area 70 and into the patient's mouth.
29 V. Retraction for Storage A further feature of the aerosol medication apparatus 10 is that it can be 31 retracted for convenient storage and portability. For this purpose, the chamber I housing 24 is coupled to the canister-holding portion 22 via a coupling mechanism 94 2 as shown in FIG. 11. The coupling mechanism 94 permits the aerosol medication 3 delivery apparatus 10 to be compactly stored by pivoting the canister-holding portion 4 22 from the position of FIGS. 1-4 to a horizontal position and then pushing the canister-holding portion 22 so that it translationally moves into the chamber housing 6 24 as shown in FIG. 10.
7 Referring to FIG. 11, the pivoting and translational movement is accomplished 8 by the structure of the coupling mechanism 94. In particular, the coupling mechanism 9 94 includes a pair of slots 96 formed in the chamber housing 24, wherein each slot 96 has an open end 98 and a closed end 100. As shown in FIG. 5, the canister-holding 11 portion 22 has a pair of pegs 102, attached thereto. In addition, the interior portion of 12 the chamber housing 24 has multiple parallel tracks 104 (shown in FIG. 10) which 13 guide the canister-holding portion 22 into the chamber housing 24.
14 To connect the chamber housing 24 and the canister-holding portion 22 together, a top end 109 of the canister-holding portion 22 is first inserted into the 16 output end 48 of the chamber housing 24 and translationally moved towards and past 17 the input end 46 so that the pegs 102 are inserted into the open ends 98 of the 18 corresponding slots 96. Each of the pegs 102 can then translationally move within its 19 respective slot 96 to the closed end 100 thereof. Thus, the canister-holding portion 22 is telescopically received within the chamber housing 24 during translational 21 movement and is able to move from the retracted position of FIG. 10 to an extended 22 position. At the extended position, both pegs 102 contact the closed ends 100 of their 23 corresponding slots 96 and the canister-holding portion 22 is then allowed to pivot to 24 the position of FIG. 4 so that the patient can use the apparatus 10. The end of the canister-holding portion 22 is curved so as to allow it to pivot relative to the chamber 26 housing 24. The foregoing coupling and retraction mechanism allow for easy use, 27 transport, and lower manufacturing costs.
28 To facilitate handling by the patient, a plurality of ribs 77 may be located 29 along the front and rear sides of the canister-holding portion 22 close to the top edge 109 thereof. These ribs 77 remain exposed when the canister-holding portion 22 is 31 retracted into the chamber portion 24 so that the patient can use these ribs to help grip I the end of the canister-holding portion 22 in order to withdraw it from the chamber 2 portion 24. After use by the patient, the cap 74 can be placed back over the 3 mouthpiece 55.
VI. Advantages of Disclosed Embodiment 6 With the embodiment disclosed above, the end result of combining the 7 specified inhalation opening area 70, the chamber housing 24, and the containment 8 baffle 51 is to administer a controllable and desired respirable dose of aerosol 9 medication to a patient for inhalation into the lungs. Further, the disclosed embodiment provides advantages over prior devices in that it incorporates an i- integrated actuator and is easier to use and is easier to store and carry given its smaller 12 size.
13 An advantageous feature of the disclosed embodiment is provided by the 14 containment baffle 51. As mentioned above, the velocity of the aerosol medication particles nearest the axis of synunetry 42 will typically be greater than that of aerosol 16 medication particles that are located further from the axis 42. The velocity of the 17 aerosol medication particles near the axis 42 may be so large as to reduce the 18 effectiveness of delivering the medication to the patient because it will cause a 19 significant portion of the aerosol medication particles to impact on the oropharyngeal region and upper airway where they have no therapeutic value and, in the case of 21 medication such as cort icosteroids. may give rise to adverse side-effects.
The 22 containment baffle 51 overcomes this potential problem by isolating the patient's 23 mouth from the location at which the greatest risk of high velocity impaction may 24 occur. The containment baffle provides this solution in a manner that is relatively inexpensive and easy to manufacture.
26 The disclosed aerosol medicatioii delivery apparatus optimizes the deposition 27 of respirable aerosol medication particles in a patient's lungs to provide a desired 28 therapeutic effect. The aerosol medication delivery apparatus also reduces the 29 importance of coordination between the actuation and inhalation maneuvers and reduces or eliminates possible side-effects caused by aerosol medication formulations 31 consisting of corticosteroids. The aerosol medication delivery apparatus also reduces I or eliminates the unpleasant taste associated with aerosol medication formulations 2 such as flunisolide and allows for convenient portability and quick use.
3 In the case of pMDls that use HFA as a propellant for flunisolide, the present 4 embodiment provides a particular advantage. Through use of the present embodiment, the respirable dosage of flunisolide delivered to the patient can be 6 controlled in a manner to closely conform to the dosage of flunisolide that had been 7 delivered using conventional prior art systems that used prior propellants, such as 8 CFC. In this manner, the dosage of flunisolide can be consistently maintained, 9 thereby benefiting administration of such medication to patients.
The shape, size, and number of openings in the inhalation opening area may 11 vary in order to ensure the administration of a desired respirable dose of a specific 12 pMDI formulation. Upon discharge the on-axis aerosol medication particles, which 13 are generally non-respirable and have a higher inertia than the respirable particles, 14 collide with the interior center portion of the containment baffle resulting in a reduction in the number of larger (non-respirable) aerosol medication particles, and 16 the division of larger (non-respirable) aerosol medication particles into smaller 17 respirable particles.
18 By sealing off (except for the inhalation opening area) the output end of the 19 chamber, the containment baffle contributes to maintaining a high pressure zone in the chamber which allows for the deflection of most slower moving respirable aerosol 21 medication particles away from the containment baffle and into the chamber for 22 containment until inhaled by the patient through the inhalation opening area. The 23 containment of the respirable aerosol medication particles in the chamber provides the 24 patient with more time to inhale the aerosol medication particles and, therefore, reduces the importance of exact coordination between the discharge maneuver and 26 inhalation.
28 VII. Exemplary embodiment 29 In one exemplary embodiment, shown in FIGS. 1-1 l, the canister-holding portion 22 is approximately 7.5 cm in height and is approximately 2.5 by 2.5 cm in 31 cross section. The chamber housing 24 is approximately 8 cm in length and has an I oval-shaped cross section with dimensions of approximately 49 mm by 33 mm.
The 2 mouthpiece 55 is approximately 1.5 cm in length. The canister-holding portion, the 3 chamber housing, and the end cap are formed of a suitable hard, durable plastic, such 4 as polypropylene. The discharge orifice 36 has a diameter of approximately 0.011 inches. In a present embodiment, the containment baffle 51 has a width of 6 approximately 27 mm and a height of approximately 15 mm at the center and 5 mm 7 at the side edges.
8 For purposes of this embodiment, it is assumed that the pMDI canister 9 contains a 0.06% w/v to 0.24% w/v mixture of liquid medication, such as flunisolide in ethanolic solution and HFA as a propellant. It is understood that the pMDI
canister 11 30 can also contain other liquids and other mixtures without departing from the spirit 12 of the invention.
14 VIII. Alternative embodiments Referring to FIGS. 12 and 13, another embodiment of an aerosol delivery 16 apparatus 110 is shown. This embodiment is similar to the embodiment shown in 17 FIGS. 1-11 and like components are labeled with the same numerals. In the 18 embodiment of FIGS. 12 and 13, the containment baffle 151 is located at an upstream 19 end of the passageway defined in the mouthpiece 55. The containment baffle 151 in this embodiment is convex in shape and diverts flow around an on-axis trajectory. In 21 the embodiment of FIGS. 12 and 13, a chamber housing 124 has four squared-off 22 sides 125, 126, 127, and 128. 'fhe squared-off sides may facilitate grippine of the 23 device.
24 Referring to FIGS. 14-16, there are depicted alternative embodiments of the containment baffle. In FIG. 14, a containment baffle 251 has a screen-like structure 26 forming a plurality of openings defined between a crisscrossed mesh 252.
The surface 27 area provided by the mesh 252. combined with the relatively small areas of the 28 openings, serves to prevent aerosol particles having a high velocity from passing to 29 the patient. In FIG. 15, a containment baffle 351 has a plurality of small circular openings formed around a periphery of a solid central portion 362. Like the previous 31 embodiments, the embodiment of FIG. 15 provides a surface area 362, combined with 1 the relatively small openings, serves to prevent aerosol particles having a high 2 velocity from passing to the patient. In FIG. 16, a containment baffle 451 has four 3 relatively large openings formed around the periphery a solid dish-shaped central 4 portion 462. The dish-shaped central portion 462 is connected to the remainder of the chamber body by one or more ribs 463. Like the previous embodiments, the 6 embodiment of FIG. 16 provides a surface area 462, that serves to prevent aerosol 7 particles having a high velocity from passing to the patient.
8 Referring to FIGS. 17 and 18, there is shown an alternate embodiment 512 of 9 an aerosol delivery apparatus. The embodiment of FIGS. 17 and 18 includes an aerosol delivery apparatus 510. The apparatus 510 includes a chamber housing 11 which defines an interior space 539. The apparatus 510 does not include an integrated 12 canister-holding portion. Instead, the chamber housing 524 has a backpiece 527. The 13 backpiece 527 is made of an elastomeric material and is fitted over the upstream end -4 of the chamber housing 524. The backpiece 527 has an opening 529 located centrally therein. The opening 529 is sized to receive the mouthpiece end of a separate pMDI
16 actuator boot. In a preferred embodiment, the opening 529 is sized so that the 17 mouthpiece of the pMDI actuator boot fits snugly into the opening 529.
Because the I8 backpiece 527 is formed of an elastomeric material, it is resilient and the opening 529 19 in the backpiece can be stretched, thereby enabling it acconunodate actuator boot mouthpieces of various sizes and shapes. The backpiece 527 may be similar to the 21 backpiece described in U.S. Pat. No. 4,470.412 or in Ser. No. 08/248,716, the entire 22 disclosure of which is incorporated by reference herein.
23 Located at a downstream end of the chamber housing 524 is a mouthpiece 555.
24 Also located at the downstream end of the chamber housing 524 is a containment baffle 551. The containment baffle 551 may be similar to the containment baffle 51 in 26 the above described embodiment. Located around the periphery of the containment 27 baffle center portion 562 is an inhalation opening area 570. The inhalation opening 28 area 570 includes four arcuate shaped openings. In the embodiment of FIGS.
17 and 29 18, the containment baffle 551 is located at the downstream end of the mouthpiece 555, although in altemative enibodiments, the containment baffle may be located at 31 the upstream end of the mouthpiece or anywhere along the length of the mouthpiece.
1 With the embodiment of FIGS. 17 and 18, the patient inserts the actuator boot 2 mouthpiece into the opening 529 and inserts the pMDI canister into the actuator boot.
3 The patient presses down on the pMDI canister to cause a plume of aerosol 4 medication to be discharged from the stem of the pMDI canister out of the mouthpiece of the actuator boot and into the interior space 539. The patient inhales the aerosol 6 from the interior space 539 via the mouthpiece 555 of the apparatus 510.
7 Another embodiment of the aerosol medication delivery apparatus is shown in 8 FIGS. 19 and 20. An aerosol delivery apparatus 610 includes a chamber housing 624 9 defining an interior space 639. The apparatus 610 also includes an elastomeric backpiece 627 which may be similar to the backpiece in the embodiment shown in t t FIGS. 17 and 18. The apparatus 610 includes a containment baffle 651. The 12 containment baffle 651 is located at the downstream end of the chamber housing 624 13 just upstream of the mouthpiece 655. The containment baffle 651 includes an 14 inhalation opening area 670 located around the periphery of the containment baffle 651. In the embodiment of FIGS. 19 and 20, the containment baffle 651 may be 16 formed of a single piece of material with the chamber housing 624. The mouthpiece 17 655 may be formed of a separate piece of material that is coupled to the downstream 18 end of the chamber housing 624. The embodiment of FIGS. 19 and 20 may be used in 19 a similar manner as the embodiment of FIGS. 17 and 18.
Still another embodiment of the aerosol medication delivery apparatus is 21 shown in FIGS. 21 and 22. This embodiment of the aerosol delivery apparatus is 22 particularly suited for use by a mechanically ventilated patient (i.e. a patient using a 23 ventilator). In FIG. 21, an aerosol delivery apparatus 710 includes components that 24 are similar to the previous embodiments, in particular the embodiment of FIGS. 17 and 18. A chamber housing 724 defines an interior space 739. The apparatus 710 is 26 intended to be positioned in a ventilator circuit, in particular in the air passageway that 27 provides inspiratory air flow from a ventilator to the patient. The chamber housing 28 724 includes a first opening 727 located in a first tubular extension 728 extending 29 from the upstream end 746 of the chamber housing 724 and a second opening located in a second tubular extension 756 that extends from the downstream end 31 of the chamber housing 724. The first opening 727 connects to tubing 731 that leads i to the ventilator (not shown) and the second opening 7551eads to tubing, a mask, a 2 mouthpiece, or other suitable means (not shown) of providing air from the ventilator 3 to the patient. Located at the upstream end of the chamber 724 is a receptacle 722. At 4 the bottom of the receptacle 722 is a well 734 adapted to receive the stem of a pMDI
canister. The wel1734 extends into a rib 735 that extends across the entrance into the 6 interior space 739 of the chamber housing 724. The rib 735 may be located at or 7 along the extension 728. The rib 735 includes a discharge opening 736 that 8 communicates with the we11734. The discharge opening 736 is oriented toward the 9 interior space 739. The receptacle 722, the rib 735, and the discharge opening 736 are integrated with the chamber housing 724 forming part of the aerosol delivery 1 t apparatus 710, (i.e. the receptacle and chamber housing form an integrated unit). In 12 one embodiment the receptacle 722, the rib 735, and the discharge opening 736 are 13 formed of the same piece of material as the chamber housing 724, or alternatively, 14 they may be fonned of separate pieces. Further disclosure regarding an integrated chamber housing and canister receptacle is included in U.S. Pat. No.
5,012,804.
16 Located at the downstream end 748 of the chamber 724 is a containment baffle 17 751. The containment baffle 751 may be located at the downstream end of the 18 chamber housing 724 or along the extension 756. The containment baffle 751 19 includes an inhalation opening area 7701ocated around the periphery of the containment baffle 751.
21 The embodiment of FIGS. 21 and 22 may be used in a similar manner as the 22 device disclosed in U.S. Pat. No. 5,012,804. The apparatus 710 may be positioned in 23 the inspiratory flow path from the ventilator to the patient when the patient is initially 24 placed on the ventilator. The apparatus 710 is then left in place until needed.
Alternatively, the apparatus 710 may be positioned in the inspiratory flow path of the 26 ventilator circuit just prior to when a dose of aerosol medication is to be delivered to a 27 ventilated patient. A pMDI canister is positioned in the receptacle 722 and actuated.
28 The medication from the pMDI canister is conveved with the inspiratory flow from 29 the ventilator to the patient. As in tlie previously described embodiments, the containmcnt baffle 751 reduces on-axis non-respirable particles.
I The invention may be embodied in other forms than those specifically 2 disclosed herein without departing from its spirit or essential characteristics. The 3 described embodiments are to be considered in all respects only as illustrative and not 4 restrictive, and the scope of the invention is commensurate with the appended claims rather than the foregoing descriptions.
Claims (20)
1. An aerosol medication delivery apparatus for use with a pressurized metered dose inhaler canister having medication and a propellant contained therein under pressure, where the pressurized metered dose inhaler canister has a discharge orifice from which the medication and the propellant can be discharged forming an aerosol, the apparatus comprising:
a chamber housing having an input end and an output end and defining an interior space, wherein said input end is adapted to receive a medication discharged from the discharge orifice of a pressurized metered dose inhaler canister into said interior space and said chamber housing having a central axis and a downstream end; and a containment baffle located at said downstream end of said chamber housing to partially block said output end, wherein said containment baffle has a curved portion located along and intersecting said central axis of said chamber housing, wherein said curved portion of said containment baffle remains fixed along said central axis relative to said output end of said chamber housing, and wherein said curved portion has a concave surface facing said input end of said chamber housing.
a chamber housing having an input end and an output end and defining an interior space, wherein said input end is adapted to receive a medication discharged from the discharge orifice of a pressurized metered dose inhaler canister into said interior space and said chamber housing having a central axis and a downstream end; and a containment baffle located at said downstream end of said chamber housing to partially block said output end, wherein said containment baffle has a curved portion located along and intersecting said central axis of said chamber housing, wherein said curved portion of said containment baffle remains fixed along said central axis relative to said output end of said chamber housing, and wherein said curved portion has a concave surface facing said input end of said chamber housing.
2. The apparatus of claim 1 further comprising a mouthpiece located at said output end of said chamber housing, wherein said mouthpiece forms said containment baffle.
3. The apparatus of claim 2 wherein said interior space of said chamber housing has a first cross-sectional area perpendicular to said central axis, and wherein said mouthpiece defines an interior space having a second cross-sectional area perpendicular to said central axis, wherein said second cross-sectional area is less than said first cross-sectional area.
4. The apparatus of claim 2 or 3 further comprising a curved shoulder portion transitioning between said chamber housing and said mouthpiece.
5. The apparatus of claim 4 wherein an inner surface of said curved shoulder portion is concave.
6. The apparatus of any one of claims 2-5 wherein said containment baffle is located at a downstream end of said mouthpiece.
7. The apparatus of any one of claims 2-5 wherein said containment baffle is located at an upstream end of said mouthpiece.
8. The apparatus of any one of claims 1-7 wherein said containment baffle defines an inhalation opening area located around a periphery thereof.
9. The apparatus of claim 8 wherein said inhalation opening area comprises a plurality of openings.
10. The apparatus of claim 9 wherein said openings are arcuate shaped.
11. An aerosol medication delivery apparatus for use with a pressurized metered dose inhaler canister having medication and a propellant contained therein under pressure, where the pressurized metered dose inhaler canister has a discharge orifice from which the medication and the propellant can be discharged forming an aerosol, the apparatus comprising:
a chamber housing having an input end and an output end and defining an interior space, wherein said input end is adapted to receive a medication discharged from the discharge orifice of a pressurized metered dose inhaler canister into said interior space and said chamber housing having a central axis and a downstream end; and a containment baffle located at said downstream end of said chamber housing to partially block said output end, wherein said containment baffle has a curved portion located along and intersecting said central axis of said chamber housing, wherein said curved portion of said containment baffle remains fixed along said central axis relative to said output end of said chamber housing, and wherein said curved portion has a convex surface facing said input end of said chamber housing.
a chamber housing having an input end and an output end and defining an interior space, wherein said input end is adapted to receive a medication discharged from the discharge orifice of a pressurized metered dose inhaler canister into said interior space and said chamber housing having a central axis and a downstream end; and a containment baffle located at said downstream end of said chamber housing to partially block said output end, wherein said containment baffle has a curved portion located along and intersecting said central axis of said chamber housing, wherein said curved portion of said containment baffle remains fixed along said central axis relative to said output end of said chamber housing, and wherein said curved portion has a convex surface facing said input end of said chamber housing.
12. The apparatus of claim 11 further comprising a mouthpiece located at said output end of said chamber housing, wherein said mouthpiece forms said containment baffle.
13. The apparatus of claim 12 wherein said interior space of said chamber housing has a first cross-sectional area perpendicular to said central axis, and wherein said mouthpiece defines an interior space having a second cross-sectional area perpendicular to said central axis, wherein said second cross-sectional area is less than said first cross-sectional area.
14. The apparatus of claim 12 or 13 further comprising a curved shoulder portion transitioning between said chamber housing and said mouthpiece.
15. The apparatus of claim 14 wherein an inner surface of said curved shoulder portion is concave.
16. The apparatus of any one of claims 12-15 wherein said containment baffle is located at a downstream end of said mouthpiece.
17. The apparatus of any one of claims 12-15 wherein said containment baffle is located at an upstream end of said mouthpiece.
18. The apparatus of any one of claims 11-17 wherein said containment baffle defines an inhalation opening area located around a periphery thereof.
19. The apparatus of claim 18 wherein said inhalation opening area comprises a plurality of openings.
20. The apparatus of claim 19 wherein said openings are arcuate shaped.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2689736A CA2689736C (en) | 1997-09-26 | 1998-09-16 | Aerosol medication delivery apparatus and system |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/938,686 US6345617B1 (en) | 1997-09-26 | 1997-09-26 | Aerosol medication delivery apparatus and system |
| US08/938,686 | 1997-09-26 | ||
| PCT/IB1998/001681 WO1999016490A1 (en) | 1997-09-26 | 1998-09-16 | Aerosol medication delivery apparatus and system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2689736A Division CA2689736C (en) | 1997-09-26 | 1998-09-16 | Aerosol medication delivery apparatus and system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2304498A1 CA2304498A1 (en) | 1999-04-08 |
| CA2304498C true CA2304498C (en) | 2010-01-05 |
Family
ID=25471799
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2790025A Abandoned CA2790025A1 (en) | 1997-09-26 | 1998-09-16 | Aerosol medication delivery apparatus and system |
| CA2689736A Expired - Lifetime CA2689736C (en) | 1997-09-26 | 1998-09-16 | Aerosol medication delivery apparatus and system |
| CA002304498A Expired - Lifetime CA2304498C (en) | 1997-09-26 | 1998-09-16 | Aerosol medication delivery apparatus and system |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2790025A Abandoned CA2790025A1 (en) | 1997-09-26 | 1998-09-16 | Aerosol medication delivery apparatus and system |
| CA2689736A Expired - Lifetime CA2689736C (en) | 1997-09-26 | 1998-09-16 | Aerosol medication delivery apparatus and system |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6345617B1 (en) |
| EP (1) | EP1019127B1 (en) |
| JP (2) | JP2001518323A (en) |
| AR (1) | AR013968A1 (en) |
| AU (1) | AU739002B2 (en) |
| CA (3) | CA2790025A1 (en) |
| DE (1) | DE69819541T2 (en) |
| WO (1) | WO1999016490A1 (en) |
| ZA (1) | ZA988203B (en) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5823179A (en) * | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
| US6345617B1 (en) | 1997-09-26 | 2002-02-12 | 1263152 Ontario Inc. | Aerosol medication delivery apparatus and system |
| US6293279B1 (en) | 1997-09-26 | 2001-09-25 | Trudell Medical International | Aerosol medication delivery apparatus and system |
| SE9704185D0 (en) * | 1997-11-14 | 1997-11-14 | Astra Pharma Prod | Inhalation device |
| US7967011B2 (en) * | 1997-11-14 | 2011-06-28 | Astrazeneca Ab | Inhalation device |
| US20060213505A1 (en) * | 1997-11-14 | 2006-09-28 | Astrazeneca Ab | Inhalation device |
| US6397837B1 (en) * | 1999-07-22 | 2002-06-04 | Martin W. Ferris | Inhaler assistive device |
| GB2360219A (en) | 2000-03-18 | 2001-09-19 | Astrazeneca Uk Ltd | Inhaler |
| AU4867001A (en) | 2000-04-11 | 2001-10-23 | Trudell Medical International | Aerosol delivery apparatus with positive expiratory pressure capacity |
| US6501052B2 (en) * | 2000-12-22 | 2002-12-31 | Chrysalis Technologies Incorporated | Aerosol generator having multiple heating zones and methods of use thereof |
| US6698422B2 (en) * | 2001-03-12 | 2004-03-02 | Birdsong Medical Devices, Inc. | Canister inhaler having a spacer and easy to operate lever mechanism and a flexible, elastic mouthpiece |
| AU2002238801A1 (en) * | 2001-03-20 | 2002-10-03 | Trudell Medical International | Nebulizer apparatus and method |
| EP1414508B1 (en) * | 2001-06-26 | 2011-04-20 | Norton Healthcare Limited | An improved aerosol actuator |
| US7767872B2 (en) * | 2001-09-06 | 2010-08-03 | Mpg Biotechnologies, Llc | Thimerosal removal device |
| US8440791B2 (en) * | 2001-09-06 | 2013-05-14 | Mgp Biotechnologies, Llc | Thimerosal removal device |
| US20030205226A1 (en) | 2002-05-02 | 2003-11-06 | Pre Holding, Inc. | Aerosol medication inhalation system |
| WO2003092777A1 (en) * | 2002-05-03 | 2003-11-13 | Trudell Medical International | Aerosol medication delivery apparatus with narrow orifice |
| US6904908B2 (en) | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
| US7360537B2 (en) * | 2003-04-16 | 2008-04-22 | Trudell Medical International | Antistatic medication delivery apparatus |
| US8235036B2 (en) * | 2005-09-09 | 2012-08-07 | Vedat Obuz | Portable universal inhaler system |
| WO2007041669A2 (en) * | 2005-10-04 | 2007-04-12 | Sp Medical Llc | Metered dose inhaler having spacing device |
| WO2008008021A1 (en) * | 2006-07-14 | 2008-01-17 | Astrazeneca Ab | Inhalation system and delivery device for the administration of a drug in the form of dry powder. |
| MX2009001944A (en) | 2006-08-21 | 2009-04-16 | Trudell Medical Int | Respiratory muscle endurance training device and method for the use thereof. |
| WO2009070851A2 (en) * | 2007-12-08 | 2009-06-11 | Dimitrios Efthimiou | Personal air filter with amplifier and vibrator |
| WO2009105515A2 (en) | 2008-02-21 | 2009-08-27 | Trudell Medical International | Respiratory muscle endurance training device and method for the use thereof |
| US8251876B2 (en) * | 2008-04-22 | 2012-08-28 | Hill-Rom Services, Inc. | Breathing exercise apparatus |
| US8539951B1 (en) | 2008-05-27 | 2013-09-24 | Trudell Medical International | Oscillating positive respiratory pressure device |
| US8327849B2 (en) | 2008-10-28 | 2012-12-11 | Trudell Medical International | Oscillating positive expiratory pressure device |
| US9149589B2 (en) | 2009-02-23 | 2015-10-06 | Trudell Medical International | Method and device for performing orientation dependent oscillating positive expiratory pressure therapy |
| US8485179B1 (en) | 2009-02-23 | 2013-07-16 | Trudell Medical International | Oscillating positive expiratory pressure device |
| EP2618876B1 (en) * | 2010-09-21 | 2018-11-14 | Koninklijke Philips N.V. | Valved holding chamber including valve retention system |
| JP5876068B2 (en) | 2010-11-30 | 2016-03-02 | テバ ファーマシューティカル インダストリーズ リミテッド | Aspirator and housing cap for aspirator |
| ES2687150T3 (en) | 2011-06-06 | 2018-10-23 | Trudell Medical International | Oscillating positive expiratory pressure device |
| US8695589B2 (en) | 2011-12-06 | 2014-04-15 | Anthony J. Mullane | Inhaler assist device |
| US9180271B2 (en) | 2012-03-05 | 2015-11-10 | Hill-Rom Services Pte. Ltd. | Respiratory therapy device having standard and oscillatory PEP with nebulizer |
| US9364622B2 (en) | 2012-04-20 | 2016-06-14 | Fsc Laboratories, Inc. | Inhalation devices and systems and methods including the same |
| US9517315B2 (en) | 2012-11-30 | 2016-12-13 | Trudell Medical International | Oscillating positive expiratory pressure device |
| CA151549S (en) | 2013-02-14 | 2014-06-04 | Clement Clarke Int Ltd | Spacer for an asthma inhaler |
| USD735316S1 (en) | 2013-03-11 | 2015-07-28 | Fsc Laboratories, Inc. | Inhalation spacer |
| WO2015003249A1 (en) | 2013-07-12 | 2015-01-15 | Trudell Medical International | Huff cough simulation device |
| TWI568463B (en) | 2013-07-12 | 2017-02-01 | Ｈ 斯圖爾特 坎貝爾 | Mouthpiece for inhalers |
| US9849257B2 (en) | 2013-08-22 | 2017-12-26 | Trudell Medical International | Oscillating positive respiratory pressure device |
| WO2015053361A1 (en) * | 2013-10-11 | 2015-04-16 | 株式会社リーチハイアー | Inhalation aid for oral powder |
| US10363383B2 (en) | 2014-02-07 | 2019-07-30 | Trudell Medical International | Pressure indicator for an oscillating positive expiratory pressure device |
| GB201408561D0 (en) * | 2014-05-14 | 2014-06-25 | The Technology Partnership Plc | Aerosolisation engine for liquid drug delivery |
| USD748242S1 (en) * | 2014-07-11 | 2016-01-26 | H. Stuart Campbell | Inhaler mouthpiece |
| US10004872B1 (en) | 2015-03-06 | 2018-06-26 | D R Burton Healthcare, Llc | Positive expiratory pressure device having an oscillating valve |
| CN205924624U (en) * | 2015-05-12 | 2017-02-08 | 深圳瑞之谷医疗科技有限公司 | Medicine glass subassembly and medical vaporizer |
| WO2017017657A1 (en) | 2015-07-30 | 2017-02-02 | Trudell Medical International | Combined respiratory muscle training and oscillating positive expiratory pressure device |
| USD778429S1 (en) | 2015-09-02 | 2017-02-07 | Trudell Medical International | Respiratory treatment device |
| USD780906S1 (en) | 2015-09-02 | 2017-03-07 | Trudell Medical International | Respiratory treatment device |
| EP3383465B1 (en) | 2015-12-04 | 2021-02-03 | Trudell Medical International | Huff cough simulation device |
| MX2018014121A (en) | 2016-05-19 | 2019-04-29 | Trudell Medical Int | Smart valved holding chamber. |
| US10537693B2 (en) | 2016-05-30 | 2020-01-21 | Medical Developments International Limited | Collapsible disposable spacer for metered dose inhalers |
| EP3984579A1 (en) | 2016-07-08 | 2022-04-20 | Trudell Medical International | Smart oscillating positive expiratory pressure device |
| US10786638B2 (en) | 2016-07-08 | 2020-09-29 | Trudell Medical International | Nebulizer apparatus and method |
| AU2017371392B2 (en) * | 2016-12-06 | 2023-06-29 | Heath Rainbow | Inhaler housing |
| WO2018104805A1 (en) | 2016-12-09 | 2018-06-14 | Trudell Medical International | Smart nebulizer |
| CA3059532A1 (en) | 2017-05-03 | 2018-11-08 | Trudell Medical International | Combined oscillating positive expiratory pressure therapy and huff cough simulation device |
| DE102017219364B4 (en) | 2017-10-27 | 2022-07-07 | Weiss Klimatechnik Gmbh | Air conditioner and method for disinfecting an air conditioner |
| JP7312754B2 (en) | 2018-01-04 | 2023-07-21 | トゥルーデル メディカル インターナショナル | Smart vibrating positive expiratory pressure device |
| US10953278B2 (en) | 2018-02-02 | 2021-03-23 | Trudell Medical International | Oscillating positive expiratory pressure device |
| WO2019236662A1 (en) | 2018-06-05 | 2019-12-12 | Teleflex Medical Incorporated | Valved spacer for inhalation device |
| WO2020102229A1 (en) | 2018-11-14 | 2020-05-22 | Loop Laboratories, LLC | Inhalant dispensing system and apparatus |
| CN114269410A (en) * | 2019-05-24 | 2022-04-01 | 蓝海集团有限责任公司 | Compact spacer for metered dose inhalers |
| GB201909172D0 (en) * | 2019-06-26 | 2019-08-07 | Royal College Of Art | Inhaler |
| WO2021038467A1 (en) | 2019-08-27 | 2021-03-04 | Trudell Medical International | Smart oscillating positive expiratory pressure device |
| USD1010101S1 (en) | 2020-09-18 | 2024-01-02 | Trudell Medical International | Holding chamber |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2670739A (en) | 1951-07-02 | 1954-03-02 | Charles M Mcneill | Inhaler |
| GB975754A (en) | 1961-05-15 | 1964-11-18 | Pfizer Ltd | Medicament administering apparatus |
| FR1322998A (en) * | 1962-02-23 | 1963-04-05 | Improvements to aerosol production devices | |
| GB1017032A (en) | 1963-12-12 | 1966-01-12 | Aerosmoke Ltd | Aerosol compositions |
| DE1972590U (en) | 1964-06-15 | 1967-11-16 | Asmund S Laerdal | VALVE FOR REVIVAL APPARATUS. |
| US3565071A (en) | 1968-09-19 | 1971-02-23 | Abbott Lab | Self-regulating therapeutic inhaler |
| US3809084A (en) | 1970-02-16 | 1974-05-07 | American Cyanamid Co | Pressurized portable dispenser |
| US3643686A (en) | 1970-10-21 | 1972-02-22 | Ewald Koegel | High-velocity breathing valve |
| US3838686A (en) | 1971-10-14 | 1974-10-01 | G Szekely | Aerosol apparatus for inhalation therapy |
| US3809294A (en) | 1973-06-27 | 1974-05-07 | American Cyanamid Co | Dispensing lung contacting powdered medicaments |
| US3895111A (en) | 1973-06-27 | 1975-07-15 | American Cyanamid Co | Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate |
| US3994421A (en) | 1975-09-29 | 1976-11-30 | American Cyanamid Company | Unitary therapeutic aerosol dispenser |
| SE411705B (en) | 1976-11-09 | 1980-02-04 | Draco Ab | DEVICE FOR GENERATION OF A SHIELD, ESSENTIAL FUEL-FREE AEROSOL |
| GB2000555A (en) | 1977-07-01 | 1979-01-10 | Ici Ltd | Aerosol dispensing device |
| GR69682B (en) | 1978-09-11 | 1982-07-08 | Newhouse Michael T | |
| SE415957B (en) | 1979-02-16 | 1980-11-17 | Draco Ab | Aerosol inhalation device |
| SE433443B (en) * | 1981-09-15 | 1984-05-28 | Draco Ab | Aerosol inhalation device |
| US4509515A (en) * | 1982-02-23 | 1985-04-09 | Fisons Plc | Inhalation device |
| US4470412A (en) | 1982-03-19 | 1984-09-11 | Trutek Research, Inc. | Inhalation valve |
| DE3371745D1 (en) | 1983-08-02 | 1987-07-02 | Trutek Research Inc | Inhalation valve |
| FI69962C (en) | 1983-12-28 | 1986-09-12 | Huhtamaeki Oy | INHALATIONSANORDNING |
| US4637528A (en) | 1984-01-19 | 1987-01-20 | William H. Rorer, Inc. | Articulated joint in aerosol medicament dispenser |
| SE453566B (en) * | 1986-03-07 | 1988-02-15 | Draco Ab | POWDER INHALATOR DEVICE |
| FI89458C (en) | 1986-11-06 | 1993-10-11 | Leiras Oy | INHALERINGSANORDNING |
| JPS63143081A (en) | 1986-12-05 | 1988-06-15 | メクト株式会社 | Inhalator |
| US4796614A (en) * | 1987-02-26 | 1989-01-10 | Trutek Research, Inc. | Collapsible inhalation valve |
| JPH0199570A (en) * | 1987-09-30 | 1989-04-18 | Bootran Medical Technol Inc | Method and apparutus for inhalation |
| IT1217890B (en) | 1988-06-22 | 1990-03-30 | Chiesi Farma Spa | DOSED AEROSOL INHALATION DEVICE |
| US4852561A (en) * | 1988-07-27 | 1989-08-01 | Sperry C R | Inhalation device |
| US5012803A (en) * | 1989-03-06 | 1991-05-07 | Trudell Medical | Modular medication inhaler |
| US5012804A (en) | 1989-03-06 | 1991-05-07 | Trudell Medical | Medication inhaler with adult mask |
| GB8908647D0 (en) | 1989-04-17 | 1989-06-01 | Glaxo Group Ltd | Device |
| GB8915420D0 (en) | 1989-07-05 | 1989-08-23 | Fisons Plc | Inhalation device |
| GB8917775D0 (en) * | 1989-08-03 | 1989-09-20 | Atomic Energy Authority Uk | Aerosol inhaler |
| IT1237118B (en) * | 1989-10-27 | 1993-05-18 | Miat Spa | MULTI-DOSE INHALER FOR POWDER DRUGS. |
| US5042467A (en) | 1990-03-28 | 1991-08-27 | Trudell Medical | Medication inhaler with fitting having a sonic signalling device |
| US5178138A (en) * | 1990-09-11 | 1993-01-12 | Walstrom Dennis R | Drug delivery device |
| ES2089228T3 (en) | 1990-09-12 | 1996-10-01 | Hans Bisgaard | INHALER DEVICE. |
| IT1244441B (en) | 1990-09-13 | 1994-07-15 | Chiesi Farma Spa | MOUTH INHALATION DEVICE FOR AEROSOL DRUGS |
| GB9021433D0 (en) * | 1990-10-02 | 1990-11-14 | Atomic Energy Authority Uk | Power inhaler |
| US5040527A (en) | 1990-12-18 | 1991-08-20 | Healthscan Products Inc. | Metered dose inhalation unit with slide means |
| AU651882B2 (en) * | 1991-05-14 | 1994-08-04 | Visiomed Group Limited | Aerosol inhalation device |
| RU2114642C1 (en) | 1991-05-21 | 1998-07-10 | Эбботт Лабораториз | Aerosol inhalation device |
| US5241954A (en) | 1991-05-24 | 1993-09-07 | Glenn Joseph G | Nebulizer |
| IT1248059B (en) | 1991-06-14 | 1995-01-05 | Miat Spa | MULTI-DOSE INSUFFLATOR FOR POWDER DRUGS |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| US6123075A (en) | 1991-10-15 | 2000-09-26 | Mallinckrodt, Inc. | Resuscitator regulator with carbon dioxide detector |
| DE4208880A1 (en) * | 1992-03-19 | 1993-09-23 | Boehringer Ingelheim Kg | SEPARATOR FOR POWDER INHALATORS |
| US5297543A (en) | 1992-06-24 | 1994-03-29 | Healthscan Products, Inc. | Medication inhaler mixer |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| FI95873C (en) * | 1992-10-15 | 1996-04-10 | Orion Yhtymae Oy | Valve for use with an inhaler |
| US5505194A (en) | 1994-03-23 | 1996-04-09 | Abbott Laboratories | Aerosol inhalation device having slideably and rotatably connected elliptical cylinder portions |
| SE9401220D0 (en) | 1994-04-11 | 1994-04-11 | Astra Ab | Valve |
| CA2124410A1 (en) * | 1994-05-26 | 1995-11-27 | Jean-Paul Praud | Device for the simultaneous delivery of beta 2 agonists and oxygen to a patient |
| US5477849A (en) | 1994-05-31 | 1995-12-26 | Fry; Stephen | Spacer for medication inhaler |
| GB2299512A (en) | 1995-04-06 | 1996-10-09 | Ian James Sharp | Inhaler |
| ES2168488T3 (en) | 1995-06-21 | 2002-06-16 | Sofotec Gmbh & Co Kg | PHARMACEUTICAL POWDER CARTRIDGE WITH INTEGRATED DOSING DEVICE AND INHALER FOR POWDERED MEDICINES. |
| GB9513218D0 (en) | 1995-06-29 | 1995-09-06 | Fisons Plc | Inhalation device and method |
| AUPN417395A0 (en) | 1995-07-14 | 1995-08-10 | Techbase Pty. Ltd. | An improved spacer |
| US5738087A (en) | 1995-09-21 | 1998-04-14 | King; Russell W. | Aerosol medication delivery system |
| US5617844A (en) | 1995-09-21 | 1997-04-08 | King; Russell W. | Aerosol medication delivery system |
| GB2310607A (en) | 1996-02-29 | 1997-09-03 | Norton Healthcare Ltd | Spacer device for inhalers |
| FR2751553B1 (en) | 1996-07-23 | 1999-06-11 | Pedrali Franck | PROCESS FOR IMPROVING THE DIFFUSION OF A SPRAY BRONCHODILATOR AND APPARATUSES USING THE SAME |
| US5765553A (en) | 1996-11-27 | 1998-06-16 | Diemolding Corporation | Aerosol medication delivery facemask adapter |
| GB9626263D0 (en) * | 1996-12-18 | 1997-02-05 | Innovata Biomed Ltd | Powder inhaler |
| US6345617B1 (en) | 1997-09-26 | 2002-02-12 | 1263152 Ontario Inc. | Aerosol medication delivery apparatus and system |
| US6039042A (en) | 1998-02-23 | 2000-03-21 | Thayer Medical Corporation | Portable chamber for metered dose inhaler dispensers |
| US6026807A (en) | 1998-02-27 | 2000-02-22 | Diemolding Corporation | Metered dose inhaler cloud chamber |
-
1997
- 1997-09-26 US US08/938,686 patent/US6345617B1/en not_active Expired - Lifetime
-
1998
- 1998-09-08 ZA ZA9808203A patent/ZA988203B/en unknown
- 1998-09-16 DE DE69819541T patent/DE69819541T2/en not_active Expired - Lifetime
- 1998-09-16 WO PCT/IB1998/001681 patent/WO1999016490A1/en active IP Right Grant
- 1998-09-16 EP EP98946684A patent/EP1019127B1/en not_active Expired - Lifetime
- 1998-09-16 CA CA2790025A patent/CA2790025A1/en not_active Abandoned
- 1998-09-16 JP JP2000513619A patent/JP2001518323A/en active Pending
- 1998-09-16 AU AU93644/98A patent/AU739002B2/en not_active Expired
- 1998-09-16 CA CA2689736A patent/CA2689736C/en not_active Expired - Lifetime
- 1998-09-16 CA CA002304498A patent/CA2304498C/en not_active Expired - Lifetime
- 1998-09-25 AR ARP980104800A patent/AR013968A1/en unknown
-
2009
- 2009-10-09 JP JP2009235307A patent/JP5137929B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU9364498A (en) | 1999-04-23 |
| CA2304498A1 (en) | 1999-04-08 |
| ZA988203B (en) | 2000-03-22 |
| JP2010046500A (en) | 2010-03-04 |
| US6345617B1 (en) | 2002-02-12 |
| DE69819541D1 (en) | 2003-12-11 |
| CA2689736A1 (en) | 1999-04-08 |
| CA2689736C (en) | 2012-12-18 |
| DE69819541T2 (en) | 2004-04-15 |
| EP1019127B1 (en) | 2003-11-05 |
| EP1019127A1 (en) | 2000-07-19 |
| AU739002B2 (en) | 2001-10-04 |
| JP5137929B2 (en) | 2013-02-06 |
| AR013968A1 (en) | 2001-01-31 |
| JP2001518323A (en) | 2001-10-16 |
| WO1999016490A1 (en) | 1999-04-08 |
| CA2790025A1 (en) | 1999-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2304498C (en) | Aerosol medication delivery apparatus and system | |
| CA2633447C (en) | Aerosol medication delivery apparatus and system | |
| US5699789A (en) | Dry powder inhaler | |
| JP3229887B2 (en) | Device for oral inhalation of aerosol drugs | |
| US9216259B2 (en) | Methods and apparatus for delivering aerosolized medication | |
| JPS6242628B2 (en) | ||
| EP0774986B1 (en) | Inhaler apparatus with optimisation chamber | |
| MXPA00002949A (en) | Aerosol medication delivery apparatus and system | |
| CA2197758C (en) | Inhaler apparatus with optimisation chamber |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180917 |